Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
about
Thrombotic microangiopathy with targeted cancer agentsCancer-associated thrombotic microangiopathyAntineoplastic agents and thrombotic microangiopathy.A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.A phase I study of sunitinib plus bevacizumab in advanced solid tumors.A clinicopathologic study of thrombotic microangiopathy in IgA nephropathyConcurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in a patient with metastatic neuroendocrine tumour successfully treated with rituximab-CVP.Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.TGF-β-activated kinase 1 is crucial in podocyte differentiation and glomerular capillary formation.Bevacizumab increases risk for severe proteinuria in cancer patients.Anti-VEGF Cancer Therapy in Nephrology PracticeEffects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeysRenal involvement in preeclampsia: similarities to VEGF ablation therapyMethylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugsImmunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature.Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer.Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutationProgressive bevacizumab-associated renal thrombotic microangiopathy.The risk for anemia with targeted therapies for solid tumorsKidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.Vegfa protects the glomerular microvasculature in diabetes.Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.Safety profile of new anticancer drugs.Proteinuria in preeclampsia from a podocyte injury perspective.Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.Inhibition of the VEGF signalling pathway and glomerular disorders.Sunitinib induced nephrotic syndrome and thrombotic microangiopathy.Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function.Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA.Turning a blind eye to anti-VEGF toxicities.Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.TTP-HUS associated with sunitinib.Sunitinib-induced sudden hearing loss.All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
P2860
Q24635904-0A2E5E0D-2030-4F2C-A8A7-1DE7E65E7775Q26738984-8B4BA36D-E6E2-451D-8681-8FAD73DF1F45Q30251919-9F52CD37-5B93-40F1-92EA-8CBB92AEAA75Q30414010-6C71D46A-9702-4E8C-8A2F-ABDBED4E47CFQ33386345-A99B227B-414C-4AD8-A0F7-A28D859960B6Q33397974-E71F4D8E-FC2F-4843-BAC1-EE218DD37F0CQ33402349-EF4F7575-6ECC-410B-8202-DA1FB3E6BA32Q33418425-FEC381FE-5341-4D77-99E3-A11B9B253C17Q33423350-8BBF0876-CC23-43E7-95B5-F5B1B7A08CAFQ34103389-205F14AB-E75C-4508-B20C-F299596D7091Q34124173-6E6369E1-7C13-4A40-BDF0-EF696906A57EQ34152125-4428C7EF-B998-4C7B-B8BE-36B486E0FB23Q34557530-864E405B-0C03-41C2-9B0C-2FF484467C4BQ34735646-CD0CEEF2-2645-441A-A99A-6905B1ECF63EQ35034404-96CD8292-12C2-496C-BEC4-0B9C9C0B7AC2Q35037471-FA7BDF99-EE4D-49FD-AC4F-38F13E990639Q35076287-D0D90933-CFCB-4739-99A7-5A2282FA4E28Q35295368-857BAA21-7954-4A0A-AAF2-0E86C0F01BA5Q35573669-148F0696-A321-427A-A907-2AF41442EC88Q35574176-0C3E7058-6839-4349-8AEF-A2DC67EAECC8Q35989994-EF720195-8FA8-4928-ACFD-B0534AD19F9CQ36150811-FAC09CA6-F542-473B-80DD-5BF8971A3FE4Q36339615-FE3F9CBB-6314-4C71-A019-6C258EEEAAD9Q36848153-40434E57-DE0B-4AB5-9007-6D3DAC17FC9FQ36900428-FA2D8B1F-A597-472A-B5B0-ADD12C6EBD82Q37696502-BA743A45-9265-49DD-8197-1A1B49574B72Q38161490-B712326E-73C8-4B50-BA95-CC992911242BQ38169098-D9B3264B-E0FF-4313-896C-EF2AFD001B05Q38284055-C24B230B-6151-400C-BEAF-2F546BA50D67Q39712982-A02F7039-194B-4669-96ED-D4C24490A949Q40109938-AB0A0FCA-2804-48AF-A718-F0BB833B31DAQ40336593-1973BA12-151D-4839-8013-B760A5EB3DDDQ41132593-C9378B18-F972-404C-8742-BB7FBDDD530FQ41431404-80EB0BF7-FD9A-4781-89EC-982A6D15BB5EQ42908395-45EB58D3-F540-4D4A-A4CC-9433E1E510B8Q46215271-3E01C0B9-79FC-413A-8519-D0643725F45FQ50321712-ED8B13D9-3BFF-40B5-814A-A1E0A735A9D9Q50348948-CE368549-79AB-4F67-820F-39D74B378BADQ54494865-2D2C7886-FCBB-4264-8873-2347653970B2Q57809492-DD1F5D9E-8A45-4A1A-8B45-BA3300A74040
P2860
Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Renal thrombotic microangiopat ...... tastatic renal-cell carcinoma.
@ast
Renal thrombotic microangiopat ...... tastatic renal-cell carcinoma.
@en
type
label
Renal thrombotic microangiopat ...... tastatic renal-cell carcinoma.
@ast
Renal thrombotic microangiopat ...... tastatic renal-cell carcinoma.
@en
prefLabel
Renal thrombotic microangiopat ...... tastatic renal-cell carcinoma.
@ast
Renal thrombotic microangiopat ...... tastatic renal-cell carcinoma.
@en
P2093
P1433
P1476
Renal thrombotic microangiopat ...... tastatic renal-cell carcinoma.
@en
P2093
Carlos Frangié
Carmen Lefaucheur
Christian Jacquot
Dominique Nochy
Garry S Hill
Jacques Medioni
P304
P356
10.1016/S1470-2045(07)70037-2
P577
2007-02-01T00:00:00Z